Physician profile
Prem Jayanthan
NPI 1922425446
$1,033.28
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,016 · 2022: $17.51.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $160.17 | 2019 | |
| Amgen INC. | $120.33 | 2019 | |
| Glaxosmithkline, LLC. | $80.63 | 2019 | |
| Amarin Pharma, INC. | $74.52 | 2019 | |
| Lilly USA, LLC | $68.25 | 2019 | |
| Pfizer INC. | $60.38 | 2019 | |
| Abbvie INC. | $58.47 | 2019 | |
| Merck Sharp & Dohme LLC | $57.91 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $55.87 | 2019 | |
| Astellas Pharma US INC | $53.34 | 2019 | |
| Janssen Pharmaceuticals, INC | $39.42 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.54 | 2019 | |
| Genentech USA, INC. | $36.13 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.73 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $25.92 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $17.26 | 2019 | |
| Ironshore Pharmaceuticals INC. | $17.02 | 2019 | |
| Sanofi Pasteur INC. | $13.70 | 2019 | |
| Aytu Biopharma, INC. | $13.32 | 2019 | |
| Ferring Pharmaceuticals INC. | $11.37 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prem Jayanthan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.